Showing results (131-140 of 151) with videos related to
Sort By:
Pageof 16
RMD Open|December 20, 2018
Systemic lupus erythematosus: state of the art on clinical practice guidelinesFarah Tamirou, Laurent Arnaud, Rosaria Talarico, et al.Plos One|April 27, 2018
Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvantYingxia Wen, Hung V Trinh, Christine E Linton, et al.Orphanet Journal of Rare Diseases|March 11, 2025
Pregnancy-related issues in rare and low-prevalence diseases: results of ERN transversal working group on pregnancy and family planning surveyDina Zucchi, Diana Marinello, Chiara Tani, et al.Journal of Autoimmunity|October 2, 2021
Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohortMariele Gatto, Francesca Saccon, Laura Andreoli, et al.Reproductive Health|November 26, 2025
Addressing unmet needs in pregnancy and family planning of people living with rare and low-prevalence diseases: results of the "ERN transversal working group on pregnancy and family planning" surveyGiovanni Fulvio, Diana Marinello, Dina Zucchi, et al.The Lancet. Rheumatology|February 8, 2026
Patient profiles and early response in patients with systemic lupus erythematosus initiating anifrolumab: interim analysis from the ongoing multicentre observational REVEAL studyChiara Tani, Chiara Cardelli, Luca Moroni, et al.The Lancet. Rheumatology|May 26, 2025
ERN ReCONNET-SLICC-SLEuro expert consensus on the therapeutic management of rare systemic lupus erythematosus manifestationsLaurent Arnaud, Guillermo Ruiz-Irastorza, Cynthia Aranow, et al.Arthritis & Rheumatology (Hoboken, N.J.)|April 11, 2020
Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life SettingMariele Gatto, Francesca Saccon, Margherita Zen, et al.Journal of Personalized Medicine|April 28, 2023
Early and Late Response and Glucocorticoid-Sparing Effect of Belimumab in Patients with Systemic Lupus Erythematosus with Joint and Skin Manifestations: Results from the Belimumab in Real Life Setting Study-Joint and Skin (BeRLiSS-JS)Margherita Zen, Mariele Gatto, Roberto Depascale, et al.Clinical and Experimental Rheumatology|March 14, 2023
ERN ReCONNET points to consider for treating patients living with autoimmune rheumatic diseases with antiviral therapies and anti-SARS-CoV-2 antibody productsRosaria Talarico, Giuseppe Alvise Ramirez, Sofia C Barreira, et al.Pageof 16